Skip to main content

Table 2 Clinical characteristics of 76 patients (from case reports)

From: Prevalence and risk factors related to poor outcome of patients with severe Plasmodium vivax infection: a systematic review, meta-analysis, and analysis of case reports

Clinical Characteristics Frequency (percent)
Year of publication
 - ≤ 2010 38 (50)
 - > 2010 38 (50)
Age, mean (SD) 30.1 (11.5)
Impaired consciousness
 - Yes 21 (27.6)
 - No 25 (22.4)
Pulmonary edema
 - Yes 3 (3.9)
 - No 73 (96.1)
Renal failure
 - Yes 28 (36.8)
 - No 48 (63.2)
Severe anemia
 - Yes 8 (10.5)
 - No 68 (89.5)
Bleeding
 - Yes 8 (10.5)
 - No 68 (89.5)
Jaundice
 - Yes 19 (25)
 - No 57 (75)
Acidosis
 - Yes 4 (5.3)
 - No 72 (94.7)
Hyperparasitemia
 - Yes 2 (2.6)
 - No 74 (97.4)
Respiratory distress
 - Yes 22 (28.9)
 - No 54 (71.1)
Convulsion
 - Yes 8 (10.5)
 - No 68 (89.5)
Prostration
 - Yes 1 (1.3)
 - No 75 (98.7)
Gender
 - Male 48 (64)
 - Female 27 (36)
Country of infection
 - India 59 (77.6)
 - Non-India 17 (22.4)
Days of fever 5.71 (2.58)
Cough
 - Yes 6 (7.9)
 - No 70 (92.1)
Weakness
 - Yes 9 (11.8)
 - No 67 (88.2)
Headache
 - Yes 12 (15.8)
 - No 64 (84.2)
Malaise
 - Yes 3 (3.9)
 - No 73 (96.1)
Rash
 - Yes 7 (9.2)
 - No 69 (90.8)
Urine output abnormality
 - Yes 19 (25)
 - No 57 (75)
Chills
 - Yes 36 (47.4)
 - No 40 (52.6)
Rigors
 - Yes 27 (35.5)
 - No 49 (64.5)
Abdominal pain
 - Yes 15 (19.7)
 - No 61 (80.3)
Nausea
 - Yes 6 (7.9)
 - No 70 (92.1)
Vomiting
 - Yes 15 (19.7)
 - No 61 (80.3)
Edema
 - Yes 1 (1.3)
 - No 75 (98.7)
Temperature, mean (SD) 38.5 (1.04)
Systolic blood pressure, mean (SD) 107.6 (24.5)
Diastolic blood pressure, mean (SD) 69 (15.9)
Pulse rate, mean (SD) 110.9 (19.9)
Respiratory rate, mean (SD) 30.3 (11.5)
Splenomegaly
 - Yes 23 (30.3)
 - No 53 (69.7)
Hepatomegaly
 - Yes 17 (22.4)
 - No 59 (77.6)
Hemoglobin, mean (SD) 9.47 (2.79)
Leukocyte, mean (SD) 6237.8 (2722.2)
Platelet, mean (SD) 85,360 (74,296.5)
RDT
 - Yes 43 (56.6)
 - No 33 (43.4)
Time point of severe complications
 - Before treatment (at presentation) 50 (65.8)
 - After treatment (with anti-malarial drug) 16 (21.1)
 - Before and after treatment 10 (13.2)
Complication during treatment
 - Yes 34 (44.7)
 - No 42 (55.3)
Second anti-malarial drug given
 - Yes 13 (17.1)
 - No 63 (82.9)
Discharge/recovery/parasite clearance
 - > 7 days 41 (65.1)
 - ≤ 7 days 22 (34.9)